Related Experiment Video
Updated: Jul 1, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Immunotherapy targeting EBV-expressing lymphoproliferative diseases
Catherine M Bollard1, Laurence J Cooper, Helen E Heslop
1Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Best Practice & Research. Clinical Haematology
|September 16, 2008
Summary
Epstein-Barr virus (EBV) drives non-Hodgkin's lymphoma (NHL) differently in immunocompromised versus immunocompetent patients. Cellular immunotherapy shows promise for EBV-NHL in immunodeficiency, while challenges remain for immunocompetent individuals.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Epstein-Barr virus (EBV) is linked to non-Hodgkin's lymphoma (NHL) in both immunocompetent and immunodeficient individuals.
- The EBV infection pattern in lymphoma cells dictates antigen expression and immunotherapy targets, particularly in immunodeficiency.
Purpose of the Study:
- To differentiate EBV-associated NHL in immunocompetent versus immunodeficient hosts.
- To explore therapeutic strategies for EBV-driven lymphomas based on immune status.
Main Methods:
- Analysis of EBV latency patterns (Type II vs. Type III) in NHL cells.
- Evaluation of cellular immunotherapy approaches for EBV-associated lymphomas.
Main Results:
- Immunodeficient patients' EBV-NHL exhibits Type III latency with broad antigen expression, enabling effective immunotherapy.
- Immunocompetent patients' EBV-NHL shows Type II latency with limited antigens, posing challenges for T-cell persistence and tumor evasion.
Conclusions:
- EBV-NHL management requires distinct strategies based on host immune status.
- Further research is needed to overcome T-cell therapy limitations in immunocompetent individuals with EBV-associated NHL.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...